Last reviewed · How we verify
estradiol plus MPA
At a glance
| Generic name | estradiol plus MPA |
|---|---|
| Sponsor | Peking Union Medical College Hospital |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- A Study of MK-5684 in People With Certain Solid Tumors (MK-5684-015/OMAHA-015) (PHASE2)
- Intrauterine Stent Placement Following Hysteroscopic Septum Resection (NA)
- Estrogen Receptor Beta and Mood (PHASE2)
- Efficacy and Safety of Huanjingjian Decoction in Women With Premature Ovarian Insufficiency (NA)
- Atherosclerosis, Immune Mediated Inflammation and Hypoestrogenemia in Young Women (PHASE2)
- A Study Run At Multiple Study Sites to Test Whether the SAMANTA Questionnaire That is Used to Diagnose Heavy Menstrual Bleeding (HMB), Can Also Be Used to Assess Changes of Severity of HMB in Women with HMB Who Are Treated During 12 Months with a Chronic Hormonal Treatment
- Euploid Rate of Blastocyst Derived From PPOS VS Antagonist Protocol (NA)
- Hormone Replacement Therapy for Hot Flashes and/or Vaginal Symptoms in Postmenopausal Women Receiving Tamoxifen for Breast Cancer (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- estradiol plus MPA CI brief — competitive landscape report
- estradiol plus MPA updates RSS · CI watch RSS
- Peking Union Medical College Hospital portfolio CI